Advertisement

Drug Delivery and Translational Research

, Volume 9, Issue 1, pp 379–393 | Cite as

Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades

  • Miglė Paškevičiūtė
  • Vilma PetrikaitėEmail author
Review Article
  • 159 Downloads

Abstract

Multidrug resistance (MDR) is a complex phenomenon caused by numerous reasons in cancer chemotherapy. It is related to the abnormal tumor metabolism, precisely increased glycolysis and lactic acid production, extracellular acidification, and drug efflux caused by transport proteins. There are few strategies to increase drug delivery into cancer cells. One of them is the inhibition of carbonic anhydrases or certain proton transporters that increase extracellular acidity by proton extrusion from the cells. This prevents weakly basic chemotherapeutic drugs from ionization and increases their penetration through the cancer cell membrane. Another approach is the inhibition of MDR proteins that pump the anticancer agents into the extracellular milieu and decrease their intracellular concentration. Physical methods, such as ultrasound-mediated sonoporation, are being developed, as well. To increase the efficacy of sonoporation, various microbubbles are used. Ultrasound causes microbubble cavitation, i.e., periodical pulsation of the microbubble, and destruction which results in formation of temporary pores in the cellular membrane and increased permeabilization to drug molecules. This review summarizes the main approaches to reverse MDR related to the drug penetration along with its applications in preclinical and clinical studies.

Keywords

Vacuolar-H+-ATPase Sodium-hydrogen exchanger Carbonic anhydrase ATP-binding cassette transporter pH modulator 

Notes

Compliance with ethical standard

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin [Internet]. 2018;68:7–30.  https://doi.org/10.3322/caac.21442.CrossRefGoogle Scholar
  2. 2.
    Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M, et al. The global decrease in cancer mortality: trends and disparities. Ann Oncol. 2016;27:926–33.CrossRefGoogle Scholar
  3. 3.
    Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. JNCI J Natl Cancer Inst [Internet]. 2007 [cited 2018 Mar 26];99:1441–54. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm135
  4. 4.
    Roos A. Weak acids, weak bases, and intracellular pH. Respir Physiol [Internet]. 1978 [cited 2018 Aug 6];33:27–30. Available from: http://linkinghub.elsevier.com/retrieve/pii/0034568778900804
  5. 5.
    Chang G. Multidrug resistance ABC transporters. FEBS Lett [Internet]. No longer published by Elsevier; 2003 [cited 2018 May 22];555:102–5. Available from: https://www.sciencedirect.com/science/article/pii/S0014579303010858
  6. 6.
    Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou CX, et al. The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol [Internet]. BioMed Central; 2013 [cited 2018 may 22];8:145. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23984887.
  7. 7.
    Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, et al. Clinical Role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol [Internet]. 2005 [cited 2018 Aug 7];23:1161–8. Available from: http://ascopubs.org/doi/10.1200/JCO.2005.03.033
  8. 8.
    Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JGM, Wiemer EAC, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res [Internet]. 2003 [cited 2018 Aug 7];9:827–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12576456.
  9. 9.
    Kibria G, Hatakeyama H, Akiyama K, Hida K, Harashima H. Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp. Biol Pharm Bull [Internet]. 2014 [cited 2018 Aug 8];37:1926–35. Available from: http://jlc.jst.go.jp/DN/JST.JSTAGE/bpb/b14-00529?lang=en&from=CrossRef&type=abstract
  10. 10.
    Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res [Internet]. Europe PMC Funders; 2016 [cited 2018 Aug 12];76:6851–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27742686.
  11. 11.
    Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell [Internet]. NIH Public Access; 2014 [cited 2018 Aug 12];25:719–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24856586.
  12. 12.
    Dauer P, Nomura A, Saluja A, Banerjee S. Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters [Internet]. Pancreatology. 2017 [cited 2018 Aug 12]. p. 7–12. Available from: http://linkinghub.elsevier.com/retrieve/pii/S142439031631256X
  13. 13.
    Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res [Internet]. American Association for Cancer Research; 2004 [cited 2018 Aug 12];10:2299–306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10815919.
  14. 14.
    Lee ES. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol [Internet]. 2014 [cited 2018 Aug 13];20:7864. Available from: http://www.liebertpub.com/doi/10.1089/ars.2007.1628
  15. 15.
    Hagmann W, Jesnowski R, Löhr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia [Internet]. 2010 [cited 2018 Aug 14];12:740–7. Available from: www.neoplasia.com
  16. 16.
    Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther [Internet]. 2007 [cited 2018 Aug 14];6:122–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17237272.
  17. 17.
    Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, et al. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res [Internet]. 2007 [cited 2018 Aug 14];27:2241–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17695509.
  18. 18.
    Alfarouk KO, Stock C-M, Taylor S, Walsh M, Muddathir AK, Verduzco D, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int [Internet]. BioMed Central; 2015;15:71. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4502609&tool=pmcentrez&rendertype=abstract
  19. 19.
    Ojugo ASE, McSheehy PMJ, McIntyre DJO, McCoy C, Stubbs M, Leach MO, et al. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous19F and31P probes. NMR Biomed [Internet]. 1999 [cited 2018 May 22];12:495–504. Available from: http://doi.wiley.com/10.1002/%28SICI%291099-1492%28199912%2912%3A8%3C495%3A%3AAID-NBM594%3E3.0.CO%3B2-K
  20. 20.
    Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med [Internet]. NIH Public Access; 2010 [cited 2018 May 22];51:1167–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20660380.
  21. 21.
    Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem [Internet]. American Society for Biochemistry and Molecular Biology; 1996 [cited 2018 Apr 12];271:32529–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8955077.
  22. 22.
    Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem [Internet]. 2001 [cited 2018 Apr 12];276:9519–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11120745.
  23. 23.
    Warburg O. The metabolism of carcinoma cells. J Cancer Res [Internet]. American Association for Cancer Research Journals; 1925 [cited 2018 Apr 12];9:148–63. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/jcr.1925.148
  24. 24.
    Candice Sun Hong A, Graham NA, Gu W, Braas D, Graeber TG, Christofk Correspondence HR. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4 MCT1 inhibition of cancer cells with MCT1/MCT4 reduces proliferation and tumor growth. Cell Rep [Internet]. 2016 [cited 2018 Apr 12];14:1590–601. Available from:  https://doi.org/10.1016/j.celrep.2016.01.057
  25. 25.
    Xu K, Mao X, Mehta M, Cui J, Zhang C, Mao F, et al. Elucidation of how cancer cells avoid acidosis through comparative transcriptomic data analysis. PLoS One [Internet]. Public Library of Science; 2013 [cited 2018 Apr 12];8:e71177. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23967163.
  26. 26.
    Paula S, Volkov AG, Hoek AN Van, Haines TH, Deamer DW. Permeation of protons, potassium ions, and small polar molecules through phospholipid bilayers as a function of membrane thickness. Biophys J [Internet]. 1996 [cited 2018 Apr 18];70:339–48. Available from: http://www.cell.com/biophysj/pdf/S0006-3495(96)79575-9.pdf
  27. 27.
    Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor CW, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer. 1999;80:1005–11.CrossRefGoogle Scholar
  28. 28.
    Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res [Internet]. 2011 [cited 2018 Apr 18];17:7337–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21980135.
  29. 29.
    Ishizaki J, Yokogawa K, Hirano M, Nakashima E, Sai Y, Ohkuma S, et al. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. Pharm Res [Internet]. 1996 [cited 2018 Apr 18];13:902–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8792430.
  30. 30.
    Robey IF, Nesbit LA. Investigating mechanisms of alkalinization for reducing primary breast tumor invasion. Biomed Res Int. 2013;2013:1–10.CrossRefGoogle Scholar
  31. 31.
    Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, et al. Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases. [cited 2018 Jul 26]; Available from: http://cancerres.aacrjournals.org/
  32. 32.
    Faes S, Dormond O. Systemic buffers in cancer therapy: the example of sodium bicarbonate; stupid idea or wise remedy? Med Chem (Los Angeles) [Internet]. 2015;5:540–4. Available from: https://www.omicsonline.org/open-access/systemic-buffers-in-cancer-therapy-the-example-of-sodium-bicarbonatestupid-idea-or-wise-remedy-2161-0444-1000314.php?aid=65744
  33. 33.
    McCarty MF, Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Altern Med Rev [Internet]. 2010 [cited 2018 Aug 6];15:264–72. Available from: http://www.altmedrev.com/archive/publications/15/3/264.pdf
  34. 34.
    Nishi T, Forgac M. The vacuolar (H+)-Atpases — nature’s most versatile proton pumps. Nat Rev Mol Cell Biol [Internet] 2002;3:94–103. Available from: http://www.nature.com/doifinder/10.1038/nrm729
  35. 35.
    Smith GA, Howell GJ, Phillips C, Muench SP, Ponnambalam S, Harrison MA. Extracellular and luminal pH regulation by vacuolar H+-ATPase isoform expression and targeting to the plasma membrane and endosomes. J Biol Chem [Internet]. 2016 [cited 2018 Apr 18];291:8500–15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861423/pdf/zbc8500.pdf
  36. 36.
    Xu J, Xie R, Liu X, Wen G, Jin H, Yu Z, et al. Expression and functional role of vacuolar H+-ATPase in human hepatocellular carcinoma. Carcinogenesis [Internet]. 2012 [cited 2018 Apr 18];33:2432–40. Available from: https://watermark.silverchair.com/bgs277.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaowggGmBgkqhkiG9w0BBwagggGXMIIBkwIBADCCAYwGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMhvfRL_V9Vr_ENyv1AgEQgIIBXaWMdxvFCE4qPSeF7oIgyaozdItDbYRtYgQmPF_3kCe1u2PR
  37. 37.
    Otero-Rey EM, Somoza-Martín M, Barros-Angueira F, García-García A. Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol. 2008;44:193–9.CrossRefGoogle Scholar
  38. 38.
    Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, et al. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Investig [Internet]. 2011 [cited 2018 Apr 18];91:732–43. Available from: https://www.nature.com/articles/labinvest20118.pdf
  39. 39.
    Lee Y-Y, Jeon H-K, Hong JE, Cho YJ, Ryu JY, Choi J-J, Lee SH, Yoon G, Kim WY, Do IG, Kim MK, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget [Internet] 2015;6:35040–50. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L606844230%5Cn http://dx.doi.org/10.18632/oncotarget.5319
  40. 40.
    Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin-a1, a specific inhibitor of vacuolar-type H+-Atpase, inhibits acidification and protein-degradation in lysosomes of cultured-cells. J Biol Chem. 1991;266:17707–12.Google Scholar
  41. 41.
    Lee CM, Tannock IF. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer [Internet] 2006;94:863–9. Available from: http://www.nature.com/doifinder/10.1038/sj.bjc.6603010
  42. 42.
    Zhitomirsky B, Assaraf YG. The role of cytoplasmic-to-lysosomal pH gradient in hydrophobic weak base drug sequestration in lysosomes. Cancer Cell Microenviron [Internet] 2015;2:3–9. Available from: http://www.smartscitech.com/index.php/CCM/article/view/807
  43. 43.
    McSheehy PMJ, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Cancer [Internet]. 2003 [cited 2018 Apr 19];39:532–40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0959804902006718
  44. 44.
    Kiyoshima T, Yoshida H, Wada H, Nagata K, Fujiwara H, Kihara M, et al. Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. Koul HK, editor. PLoS One [Internet]. Public Library of Science; 2013 [cited 2018 May 3];8:e80998. Available from: http://dx.plos.org/10.1371/journal.pone.0080998
  45. 45.
    Yu M, Lee C, Wang M, Tannock IF. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Sci. 2015;106:1438–47.CrossRefGoogle Scholar
  46. 46.
    Patel KJ, Lee C, Tan Q, Tannock IF. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013;19:6766–76.CrossRefGoogle Scholar
  47. 47.
    Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology [Internet]. Karger Publishers; 1998 [cited 2018 Apr 18];56:57–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9494064.
  48. 48.
    Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96:1702–13.CrossRefGoogle Scholar
  49. 49.
    Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, et al. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73.CrossRefGoogle Scholar
  50. 50.
    Ikemura K, Oshima K, Enokiya T, Okamoto A, Oda H, Mizuno T, et al. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. Cancer Chemother Pharmacol. Springer Berlin Heidelberg; 2017;79:943–9.Google Scholar
  51. 51.
    Lugini L, Federici C, Borghi M, Azzarito T, Marino ML, Cesolini A, Spugnini EP, Fais S Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem [internet]. Informa UK Ltd; 2016;31:538–45. Available from:  https://doi.org/10.3109/14756366.2015.1046062
  52. 52.
    Patil R, Kulshrestha A, Tikoo A, Fleetwood S, Katara G, Kolli B, et al. Identification of novel bisbenzimidazole derivatives as anticancer vacuolar (H+)-ATPase inhibitors. Molecules [Internet] 2017;22:1–14. Available from: http://www.smartscitech.com/index.php/CCM/article/view/807
  53. 53.
    Stadie WC, O’Brien H. The catalysis of the hydration of carbon dioxide and dehydration of carbonic acid by an enzyme isolated from red blood cells. J Biol Chem [Internet]. 1933 [cited 2018 Apr 25];103:521–9. Available from: http://www.jbc.org/
  54. 54.
    Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res [Internet]. 2004;64:6160–5.  https://doi.org/10.1158/0008-5472.CAN-03-2224.CrossRefGoogle Scholar
  55. 55.
    Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69:358–68.CrossRefGoogle Scholar
  56. 56.
    Luong-Player A, Liu H, Wang HL, Lin F. Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues. Am J Clin Pathol [Internet]. 2014 [cited 2018 Apr 20];141:219–25. Available from: https://academic.oup.com/ajcp/article-lookup/doi/10.1309/AJCPVJDS28KNYZLD
  57. 57.
    Parkkila S, Parkkila A-K, Saarnio J, Kivelä J, Karttunen TJ, Kaunisto K, et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem [Internet]. 2000 [cited 2018 Apr 20];48:1601–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11101628.
  58. 58.
    Gieling RG, Parker CA, De Costa LA, Robertson N, Harris AL, Stratford IJ, et al. Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. J Enzyme Inhib Med Chem [Internet]. 2013;28:360–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23163664.
  59. 59.
    McDonald PC, Sanghera J, Singh M, Lou Y, Vallejo M, Supuran CT, et al. Abstract 841: Therapeutic targeting of cancer cells in the hypoxic microenvironment using an orally bioavailable small molecule inhibitor of carbonic anhydrase IX. Cancer Res [Internet]. 2014 [cited 2018 Apr 27];74:841–841. Available from: http://www.ingentaconnect.com/content/10.3727/096504017X14965111926391
  60. 60.
    Riemann A, Güttler A, Haupt V, Wichmann H, Reime S, Bache M, et al. Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity. Oncol Res Featur Preclin Clin Cancer Ther [Internet]. 2017 [cited 2018 may 28];26:191–200. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28631600.
  61. 61.
    Janoniene A, Liu Z, Baranauskiene L, Mäkilä E, Ma M, Salonen J, et al. A versatile carbonic anhydrase IX targeting ligand-functionalized porous silicon nanoplatform for dual hypoxia cancer therapy and imaging. ACS Appl Mater Interfaces. 2017;9:13976–87.CrossRefGoogle Scholar
  62. 62.
    Wallert MA, Hammes D, Nguyen T, Kiefer L, Berthelsen N, Kern A, et al. RhoA Kinase (Rock) and p90 Ribosomal S6 Kinase (p90Rsk) phosphorylation of the sodium hydrogen exchanger (NHE1) is required for lysophosphatidic acid-induced transport, cytoskeletal organization and migration. Cell Signal [Internet]. NIH Public Access; 2015 [cited 2018 May 3];27:498–509. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25578862.
  63. 63.
    Amith SR, Fliegel L. Regulation of the Na+/H+ exchanger (NHE1) in breast cancer metastasis. Cancer Res [Internet]. American Association for Cancer Research; 2013 [cited 2018 may 3];73:1259–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23393197.
  64. 64.
    Xie R, Wang H, Jin H, Wen G, Tuo B, Xu J. NHE1 is upregulated in gastric cancer and regulates gastric cancer cell proliferation, migration and invasion. Oncol Rep [Internet]. 2017 [cited 2018 May 2];37:1451–60. Available from: https://www.spandidos-publications.com/10.3892/or.2017.5386
  65. 65.
    Yang X, Wang D, Dong W, Song Z, Dou K. Expression and modulation of Na+/H+ exchanger 1 gene in hepatocellular carcinoma: a potential therapeutic target. J Gastroenterol Hepatol [Internet]. 2011 [cited 2018 May 3];26:364–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21261728.
  66. 66.
    Cong D, Zhu W, Shi Y, Pointer KB, Clark PA, Shen H, et al. Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H+ extrusion, cell migration and survival. Carcinogenesis [Internet]. Oxford University Press; 2014 [cited 2018 May 3];35:2014–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24717311.
  67. 67.
    Altaf E, Huang X, Xiong J, Yang X, Deng X, Xiong M, et al. NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia. Oncol Lett. 2017;14:4256–62.CrossRefGoogle Scholar
  68. 68.
    Cragoe EJ, Woltersdorf OW, Ricking JB, Kwoxg SF, Jones JH. Pyrazine Diuretics. II. N-Amidino-3-Amino-5-Substituted 6-Halopyrazinecarboxamides. J Med Chem [Internet]. 1967 [cited 2018 May 3];10:66–75. Available from: http://pubs.acs.org/doi/abs/10.1021/jm00313a014
  69. 69.
    Pannocchia A, Revelli S, Tamponi G, Giorgianni A, Todde R, Bosia A, et al. Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells. Cell Biochem Funct. 1996;14:11–8.CrossRefGoogle Scholar
  70. 70.
    Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer. 2005;115:924–9.CrossRefGoogle Scholar
  71. 71.
    Rupprecht HJ, Vom DJ, Terres W, Seyfarth KM, Richardt G, Schultheibeta HP, et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation [Internet]. American Heart Association, Inc.; 2000 [cited 2018 may 3];101:2902–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8205693.
  72. 72.
    Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, et al. The Na+/H+exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol [Internet]. Elsevier; 2001 [cited 2018 May 3];38:E1644–50. Available from: https://www.sciencedirect.com/science/article/pii/S0735109701016084
  73. 73.
    Kathawala RJ, Gupta P, Ashby CR, Chen Z-S. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat [Internet]. Elsevier Ltd. 2015;18:1–17. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1368764614000788 Google Scholar
  74. 74.
    Kosztyu P, Bukvova R, Dolezel P, Mlejnek P. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chem Biol Interact [Internet]. Elsevier; 2014 [cited 2018 Apr 6];219:203–10. Available from: https://www.sciencedirect.com/science/article/pii/S0009279714001884?via%3Dihub
  75. 75.
    Chauvier D, Kegelaer G, Morjani H, Manfait M. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J Pharm Sci [Internet]. 2002 [cited 2018 Apr 6];91:1765–75. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022354916310619
  76. 76.
    Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S. Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol [Internet]. 2007 [cited 2018 Apr 6];30:717–25. Available from: http://www.spandidos-publications.com/10.3892/ijo.30.3.717
  77. 77.
    Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science [Internet]. 1992 [cited 2018 Jun 8];258:1650–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1360704.
  78. 78.
    Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 2008;324:95–102.CrossRefGoogle Scholar
  79. 79.
    Xia CQ, Yang JJ, Gan L-S. Breast cancer resistance protein in pharmacokinetics and drug–drug interactions. Expert Opin Drug Metab Toxicol [Internet]. 2005 [cited 2018 Apr 6];1:595–611. Available from: http://www.tandfonline.com/doi/full/10.1517/17425255.1.4.595
  80. 80.
    Iwakiri T, Okumura M, Hidaka M, Kumagai Y, Ichihara E, Kawano Y, et al. Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes. J Appl Toxicol [Internet]. 2008 [cited 2018 Apr 6];28:329–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17604344.
  81. 81.
    Tagen M, Zhuang Y, Zhang F, Harstead KE, Shen J, Schaiquevich P, et al. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett [Internet]. 2010 [cited 2018 Apr 6];4:195–201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20583968.
  82. 82.
    Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res [Internet]. American Association for Cancer Research; 2001 [cited 2018 Apr 6];61:3458–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10485464.
  83. 83.
    Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol [Internet]. 2002 [cited 2018 Apr 6];20:2943–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12089223.
  84. 84.
    Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res [Internet]. 2003 [cited 2018 Apr 6];63:1339–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12649196.
  85. 85.
    Benyahia B, Huguet S, Declèves X, Mokhtari K, Crinière E, Bernaudin JF, et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol [Internet]. 2004 [cited 2018 Apr 6];66:65–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15015771.
  86. 86.
    Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res [Internet]. 2001 [cited 2018 Apr 6];61:7225–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11585759.
  87. 87.
    de Graaf D, Sharma RC, Mechetner EB, Schimke RT, Roninson IB. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci U S A [Internet]. 1996 [cited 2018 Apr 6];93:1238–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8577747.
  88. 88.
    Kosztyu P, Dolezel P, Mlejnek P. Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells? Pharmacol Res [Internet]. 2013 [cited 2018 Apr 6];67:79–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23103446.
  89. 89.
    Czyzewski K, Styczynski J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma [Internet]. 2009 [cited 2018 Apr 6];56:202–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19309222.
  90. 90.
    Shukla S, Kouanda A, Silverton L, Talele TT, Ambudkar SV. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach. Mol Pharm [Internet]. American Chemical Society; 2014 [cited 2018 Apr 6];11:2313–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24865254.
  91. 91.
    Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther [Internet]. 2001 [cited 2018 Apr 6];298:1236–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11504826.
  92. 92.
    Miettinen S, Grènman S, Ylikomi T. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anticancer Drugs [Internet]. 2009 [cited 2018 Apr 6];20:267–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19262372.
  93. 93.
    Tseng E, Kamath A, Morris ME. Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharm Res [Internet]. Kluwer Academic Publishers-Plenum Publishers; 2002 [cited 2018 Apr 6];19:1509–15. Available from: http://link.springer.com/10.1023/A:1020460700877
  94. 94.
    Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, Nakano H, et al. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur J Pharmacol [Internet]. 2000 [cited 2018 Apr 6];408:1–10. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0014299900007433
  95. 95.
    Huls M, Russel FGM, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther [Internet]. American Society for Pharmacology and Experimental Therapeutics; 2009 [cited 2018 mar 16];328:3–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18791064.
  96. 96.
    Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat [Internet]. Springer US; 2006 [cited 2018 Mar 16];99:9–17. Available from: http://link.springer.com/10.1007/s10549-006-9175-2
  97. 97.
    Liu Y, Peng H, Zhang J-T. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol [Internet]. American Society for Pharmacology and Experimental Therapeutics; 2005 [cited 2018 mar 16];68:430–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15901850.
  98. 98.
    Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol [Internet]. Elsevier; 2012 [cited 2018 May 22];180:2490–503. Available from: https://www.sciencedirect.com/science/article/pii/S0002944012002477
  99. 99.
    Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood [Internet]. 1999 [cited 2018 May 22];94:1046–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10419897.
  100. 100.
    Burgio DE, Gosl MP, PJ MN. Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. J Pharmacol Exp Ther. 1998;287Google Scholar
  101. 101.
    Shalinsky DR, Jekunen AP, Alcaraz JE, Christen RD, Kim S, Khatibi S, et al. Regulation of initial vinblastine influx by P-glycoprotein. Br J Cancer [Internet]. 1993 [cited 2018 may 22];67:30–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8094005.
  102. 102.
    Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989;49:5002–6.Google Scholar
  103. 103.
    Qadir M, O’Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res. 2005;11:2320–6.CrossRefGoogle Scholar
  104. 104.
    Wishart GC, Bissett D, Paul J, Jodrell D, Harnett A, Habeshaw T, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol [Internet]. 1994 [cited 2018 mar 13];12:1771–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8083699.
  105. 105.
    Desai AA, Kindler HL, Taber D, Agamah E, Mani S, Wade-Oliver K, et al. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol. 2005;56:421–6.CrossRefGoogle Scholar
  106. 106.
    Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol [Internet] 1987;5:641–7. Available from: http://ascopubs.org/doi/10.1200/JCO.1987.5.4.641
  107. 107.
    Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J. 1985;109:210–7.CrossRefGoogle Scholar
  108. 108.
    Raderer M, Maca T, Kastner J, Kornek G, Weinlaender G, Hejna M, et al. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Oncol Res Treat. 1995;18:462–7.CrossRefGoogle Scholar
  109. 109.
    Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol. 1990;39:787–92.CrossRefGoogle Scholar
  110. 110.
    Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, et al. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Clin Cancer Res. 2001;7:1221–9.Google Scholar
  111. 111.
    Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res. 2004;10:4724–33.CrossRefGoogle Scholar
  112. 112.
    Wandel C, Richard BK, Kajiji S, Guengerich FP, Wilkinson GR, Wood AJJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999;59:3944–8.Google Scholar
  113. 113.
    Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol. 2003;66:1207–18.CrossRefGoogle Scholar
  114. 114.
    Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999;128:403–11.CrossRefGoogle Scholar
  115. 115.
    Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, et al. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. Springer Berlin Heidelberg; 2015;76:1273–83.Google Scholar
  116. 116.
    Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol [Internet]. 2001 [cited 2018 Feb 8];19:3130–41. Available from: http://ascopubs.org/doi/10.1200/JCO.2001.19.12.3130
  117. 117.
    Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer [Internet]. Wiley Subscription Services, Inc., A Wiley Company; 2007 [cited 2018 Feb 8];109:924–32. Available from: http://doi.wiley.com/10.1002/cncr.22492
  118. 118.
    Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res [Internet]. Kluwer Academic Publishers-Plenum Publishers; 1999 [cited 2018 Feb 9];16:478–85. Available from: http://link.springer.com/10.1023/A:1011902625609
  119. 119.
    Zhang RUI, Lu M, Zhang Z, Tian X, Wang S, Lv D. Resveratrol reverses P-glycoprotein-mediated multidrug resistance of U2OS / ADR cells by suppressing the activation of the NF- κ B and p38 MAPK signaling pathways. 2016;4147–54. Available from: p-gpGoogle Scholar
  120. 120.
    Ma W, Feng S, Yao X, Yuan Z, Liu L, Xie Y. Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells. Sci Rep [Internet]. 2016 [cited 2018 Mar 13];5:18789. Available from: https://www.nature.com/articles/srep18789.pdf?origin=ppub
  121. 121.
    Zhang SZ, Yang XN, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol [Internet]. 2004 [cited 2018 Mar 16];65:1208–16. Available from: http://molpharm.aspetjournals.org
  122. 122.
    Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst [Internet]. 1991 [cited 2018 Apr 9];83:105–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1988684.
  123. 123.
    Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12:835–42.CrossRefGoogle Scholar
  124. 124.
    Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, et al. A Phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen- independent prostate cancer. Acta Oncol (Madr) [Internet]. 2003 [cited 2018 Apr 9];42:195–201. Available from: https://www.tandfonline.com/doi/pdf/10.1080/02841860310010718
  125. 125.
    Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol [Internet]. 1995 [cited 2018 Apr 9];13:1985–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7636539.
  126. 126.
    Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein–positive acute myeloid leukemia. J Clin Oncol [Internet]. 2000 [cited 2018 Apr 9];18:1837–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10784624.
  127. 127.
    Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood [Internet]. American Society of Hematology; 2010 [cited 2018 Apr 8];116:4077–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20716770.
  128. 128.
    Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H, et al. Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncol Lett [Internet]. Spandidos Publications; 2017 [cited 2018 Apr 8];14:4349–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28959367.
  129. 129.
    Seiden M V., Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol [Internet]. Academic Press; 2002 [cited 2018 Apr 8];86:302–10. Available from: https://www.sciencedirect.com/science/article/pii/S0090825802967624
  130. 130.
    Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs [Internet]. 2005 [cited 2018 Apr 8];23:311–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16012790.
  131. 131.
    Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005;104:682–91.CrossRefGoogle Scholar
  132. 132.
    Weidner LD, Zoghbi SS, Lu S, Shukla S, Ambudkar S V, Pike VW, et al. The inhibitor Ko143 is not specific for ABCG2. J Pharmacol Exp Ther J Pharmacol Exp Ther [Internet]. 2015 [cited 2018 Mar 24];354:384–93. Available from:  https://doi.org/10.1124/jpet.115.225482
  133. 133.
    Liu T, Liu X, Li W. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget [Internet]. 2016 [cited 2018 Apr 8];7:40800–15. Available from: www.impactjournals.com/oncotarget
  134. 134.
    Ravikumar Reddy D, Khurana A, Bale S, Ravirala R, Samba Siva Reddy V, Mohankumar M, et al. Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. Springerplus [Internet]. Nature Publishing Group; 2016 [cited 2018 Apr 8];5:1618. Available from: http://springerplus.springeropen.com/articles/10.1186/s40064-016-3267-1
  135. 135.
    Quiney C, Billard C, Faussat A-M, Salanoubat C, Kolb J-P. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells. Leuk Lymphoma [Internet]. 2007 [cited 2018 Apr 8];48:1587–99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17701591.
  136. 136.
    Szafraniec MJ, Szczygieł M, Urbanska K, Fiedor L. Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2). Drug Metab Rev [Internet]. 2014 [cited 2018 Mar 21];46:459–74. Available from: http://www.tandfonline.com/doi/full/10.3109/03602532.2014.942037
  137. 137.
    Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res [Internet]. American Association for Cancer Research; 2000 [cited 2018 Mar 22];60:47–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10070958.
  138. 138.
    Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res [Internet]. 1998;58:5850–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9865745.
  139. 139.
    Allen JD, van Loevezijn A, Lakhai JM, van Der V, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. MolCancer Ther. 2002;1:417–25.Google Scholar
  140. 140.
    Tivnan A, Zakaria Z, O’Leary C, Kögel D, Pokorny JL, Sarkaria JN, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci [Internet]. Frontiers; 2015 [cited 2018 Mar 30];9:218. Available from: http://journal.frontiersin.org/Article/10.3389/fnins.2015.00218/abstract
  141. 141.
    Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM, Cotter FE. In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: A potential role in neuroblastoma therapy. Int J Cancer [Internet]. Wiley-Blackwell; 2002 [cited 2018 Mar 30];98:128–33. Available from: http://doi.wiley.com/10.1002/ijc.10159
  142. 142.
    Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, et al. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation. BMC Cancer [Internet]. BioMed Central; 2016 [cited 2018 Mar 30];16:578. Available from: http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2640-3
  143. 143.
    Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, et al. Small-molecule multidrug resistance–associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res [Internet]. 2009 [cited 2018 Apr 6];69:6573–80. Available from: http://cancerres.aacrjournals.org/content/canres/early/2008/12/31/0008-5472.CAN-09-1075.full.pdf
  144. 144.
    Shung KK. Diagnostic ultrasound: past, present, and future. J Med Biol Eng [Internet]. 2010 [cited 2018 May 22];31:371–4. Available from: http://www.jmbe.org.tw/files/917/public/917-2752-1-PB.pdf
  145. 145.
    Escoffre JM, Piron J, Novell A, Bouakaz A. Doxorubicin delivery into tumor cells with ultrasound and microbubbles. Mol Pharm. 2011;8:799–806.CrossRefGoogle Scholar
  146. 146.
    Piron J, Kaddur K, Bouakaz A. Enhancement of doxorubicin effect on cancer cell mortality with ultrasound and microbubbles. 2009 IEEE Int Ultrason Symp [Internet]. IEEE; 2009 [cited 2018 Feb 23]. p. 1803–4. Available from: http://ieeexplore.ieee.org/document/5441897/
  147. 147.
    Grainger SJ, Serna JV, Sunny S, Zhou Y, Deng CX, El-Sayed MEH. Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Mol Pharm [Internet]. 2010;7:2006–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20957996.
  148. 148.
    Marmottant P, Bouakaz A, Jong N de, Quilliet C. Buckling resistance of solid shell bubbles under ultrasound. J Acoust Soc Am [Internet]. 2011 [cited 2018 Feb 23];129:1231–9. Available from: http://asa.scitation.org/doi/10.1121/1.3543943
  149. 149.
    van Wamel A, Kooiman K, Harteveld M, Emmer M, ten Cate FJ, Versluis M, et al. Vibrating microbubbles poking individual cells: drug transfer into cells via sonoporation. J Control Release. 2006;112:149–55.CrossRefGoogle Scholar
  150. 150.
    Tachibana K, Uchida T, Ogawa K, Yamashita N, Tamura K. Induction of cell-membrane porosity by ultrasound. Lancet [Internet]. 1999 [cited 2018 Feb 23];353:1409. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673699012441
  151. 151.
    Mehier-Humbert S, Bettinger T, Yan F, Guy RH. Plasma membrane poration induced by ultrasound exposure: implication for drug delivery. J Control Release [Internet]. 2005 [cited 2018 Feb 23];104:213–22. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168365905000313
  152. 152.
    Park J, Fan Z, Deng CX. Effects of shear stress cultivation on cell membrane disruption and intracellular calcium concentration in sonoporation of endothelial cells. J Biomech [Internet]. 2011 [cited 2018 Feb 23];44:164–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003778/pdf/nihms-237233.pdf
  153. 153.
    Wang ZB, Wu F, Wang ZL, Zhang Z, Zou JZ, Liu C, et al. Targeted damage effects of high intensity focused ultrasound (HIFU) on liver tissues of Guizhou province miniswine. Ultrason Sonochem [Internet]. Elsevier; 1997 [cited 2018 May 22];4:181–2. Available from: https://www.sciencedirect.com/science/article/pii/S135041779700028X
  154. 154.
    Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøt J, Gjertsen BT, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release [Internet]. The Authors; 2016;243:172–81. Available from:  https://doi.org/10.1016/j.jconrel.2016.10.007
  155. 155.
    Sadiq AA, Zaltum MAM, Mamman HB, Adon MN, Othman NB, Dalimin MN, et al. An overview: investigation of electroporation and sonoporation techniques. Proc - 2015 2nd Int Conf Biomed Eng ICoBE 2015 [Internet]. IEEE; 2015 [cited 2018 Jul 27]. p. 1–6. Available from: http://ieeexplore.ieee.org/document/7235876/
  156. 156.
    Saulis G, Saule R. Size of the pores created by an electric pulse: microsecond vs millisecond pulses. Biochim Biophys Acta - Biomembr [Internet]. 2012. p. 3032–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0005273612002167
  157. 157.
    Shankayi Z, Firoozabadi SM. Antitumor efficiency of electrochemotherapy by high and low frequencies and repetitive therapy in the treatment of invasive ductal carcinoma in balb/c mice. Cell J [Internet]. Royan Institute; 2012 [cited 2018 Aug 6];14:110–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23508227.
  158. 158.
    Ueki TI, Uemura H, Nagashima Y, Ohta S, Ishiguro H, Kubota Y. Antitumour effect of electrochemotherapy with bleomycin on human prostate cancer xenograft. BJU Int [Internet]. 2008 [cited 2018 Aug 6];102:1467–71. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-410X.2008.07793.x
  159. 159.
    Kuriyama S, Matsumoto M, Mitoro A, Tsujinoue H, Nakatani T, Fukui H, et al. Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model. Dig Dis Sci [Internet]. Kluwer Academic Publishers-Plenum Publishers; 2000 [cited 2018 Aug 6];45:1568–77. Available from: http://link.springer.com/10.1023/A:1005565027969
  160. 160.
    Ogihara M, Yamaguchi O. Potentiation of effects of anticancer agents by local electric pulses in murine bladder cancer. Urol Res [Internet]. Springer-Verlag; 2000 [cited 2018 Aug 6];28:391–7. Available from: http://link.springer.com/10.1007/s002400000140
  161. 161.
    Sundararajan R, Raman V, Masterson V, Madhivanan S, Raakesh M, Camarillo IG. Gemcitabine + cisplatin combination electrochemotherapy for triple negative breast cancers: an in vitro Model Study. Springer, Singapore; 2016 [cited 2018 Aug 6]. p. 280–4. Available from: http://link.springer.com/10.1007/978-981-287-817-5_62
  162. 162.
    Girelli R, Prejanò S, Cataldo I, Corbo V, Martini L, Scarpa A, et al. Feasibility and safety of electrochemotherapy (ECT) in the pancreas: a pre-clinical investigation. Radiol Oncol [Internet]. De Gruyter Open; 2015 [cited 2018 Aug 6];49:147–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26029026.
  163. 163.
    Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL, Chiarion-Sileni V, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol [Internet]. 2009 [cited 2018 Aug 6];16:191–9. Available from: http://link.springer.com/10.1245/s10434-008-0204-8
  164. 164.
    NICE. Interventional procedure overview of electrochemotherapy for metastases of the skin from tunours of non-skin origin (IP984) [Internet]. 2012. Available from: https://www.nice.org.uk/guidance/gid-ip1041/documents/electrochemotherapy-for-metastases-in-the-skin-of-nonskin-origin-and-melanoma-overview2
  165. 165.
    NICE. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma | Guidance and guidelines | NICE. 2014 [cited 2018 Aug 6]; Available from: https://www.nice.org.uk/terms-and-.
  166. 166.
    NICE. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. Interv Proced Guid [Internet]. 2013 [cited 2018 Aug 6];1–7. Available from: https://www.nice.org.uk/terms-and-.
  167. 167.
    Vásquez JL, Ibsen P, Lindberg H, Gehl J. In vitro and in vivo experiments on electrochemotherapy for bladder cancer. J Urol [Internet]. 2015 [cited 2018 Aug 6];193:1009–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25245485.
  168. 168.
    Egeland C, Baeksgaard L, Johannesen H, Löfgren J, Plaschke C, Svendsen L, Gehl J, Achiam M Endoscopic electrochemotherapy for esophageal cancer: a phase I clinical study. Endosc Int Open [Internet] 2018;6:E727–34. Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/a-0590-4053
  169. 169.
    Hossen S, Hossain MK, Rahman MT, Uddin MJ. Smart nanocarrier based drug delivery systems for cancer therapy and toxicity study: a review. J Adv Res [Internet]. 2018 [cited 2018 Aug 6]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2090123218300791
  170. 170.
    Wakaskar RR. Passive and active targeting in tumor microenvironment. Int J Drug Dev Res [Internet]. International Journal of Drug Development & Research; 2017 [cited 2018 Aug 15];9:37–41. Available from: http://www.ijddr.in/drug-development/passive-and-active-targeting-in-tumor-microenvironment.php?aid=19478#20
  171. 171.
    Wang M, Thanou M. Targeting nanoparticles to cancer [Internet]. Pharmacol. Res. 2010 [cited 2018 Aug 15]. p. 90–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1043661810000794
  172. 172.
    Park KM, Baek K, Ko YH, Shrinidhi A, Murray J, Jang WH, et al. Mono-allyloxylated Cucurbit[7]uril acts as an unconventional amphiphile to form light-responsive vesicles. Angew Chemie - Int Ed [Internet]. 2018 [cited 2018 Aug 6];57:3132–6. Available from: http://doi.wiley.com/10.1002/ange.201713059
  173. 173.
    Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and Pgp siRNA to overcome drug resistance in a cancer cell line. ACS Nano. 2010;4:4539–50.CrossRefGoogle Scholar
  174. 174.
    Abdalkader R, Kawakami S, Unga J, Higuchi Y, Suzuki R, Maruyama K, et al. The development of mechanically formed stable nanobubbles intended for sonoporation-mediated gene transfection. Drug Deliv [Internet]. 2017 [cited 2018 Aug 16];24:320–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28165819.

Copyright information

© Controlled Release Society 2018

Authors and Affiliations

  1. 1.Department of Drug Chemistry, Faculty of PharmacyLithuanian University of Health SciencesKaunasLithuania
  2. 2.Institute of BiotechnologyVilnius UniversityVilniusLithuania

Personalised recommendations